Streptococcus Group A

Earn CME/CE in your profession:


Continuing Education Activity

Group A streptococci are ubiquitous bacteria encountered daily, which can potentially cause a wide range of human infections. Group A streptococci (GAS) are classified as gram-positive cocci that cause a range of diseases. GAS can be divided into greater than 100 different subtypes based on their surface ‘M-protein.’ Infections due to GAS result in acute pharyngitis, impetigo, erysipelas, and cellulitis. GAS also tends to produce manifestations of more invasive diseases, including streptococcal toxic shock syndrome and necrotizing fasciitis. In addition to acute infection, infections due to GAS result in several nonsuppurative complications, including acute rheumatic fever and post-streptococcal glomerular nephritis. This activity reviews the evaluation and treatment of Group A Strep infections and highlights the role of the interprofessional team in evaluating and treating patients with this condition.

Objectives:

  • Summarize the various types of infections typically caused by group A streptococci.

  • Identify the appropriate diagnostic approach for identifying infections caused by group A streptococci.

  • Outline the appropriate treatment options for infections caused by group A streptococci.

  • Describe the importance of improving care coordination amongst the interprofessional team to identify infections caused by group A streptococci to improve patient outcomes.

Introduction

Streptococcus pyogenes, a Lancefield group A streptococcus (GAS), is one of the most common bacteria encountered daily (see Image. Streptococcus Pyogenes Bacteria). These bacteria result in acute infections with a wide array of manifestations in adults and children and are responsible for an estimated 9,000-12,000 deaths annually in the United States.[1] Group A streptococci (GAS) are classified as gram-positive cocci that cause a range of diseases. GAS can be divided into greater than 100 different subtypes based on their surface ‘M-protein.’ Infections due to GAS result in acute pharyngitis, impetigo, erysipelas, and cellulitis. GAS also tends to produce manifestations of more invasive diseases, including streptococcal toxic shock syndrome and necrotizing fasciitis. In addition to acute infection, infections due to GAS result in several nonsuppurative complications, including acute rheumatic fever and post-streptococcal glomerular nephritis.[2]

Etiology

Group A streptococci are ubiquitous bacteria found as normal skin flora and in the environment around us. Streptococcus pyogenes grows easily on blood agar. When incubated at 35 to 37 C, they produce smooth or moist greyish-white colonies with clear margins measuring > 0.5 mm, and the colonies are surrounded by beta-hemolysis. Gram stain typically shows Gram-positive cocci that are arranged in chains. GAS is both catalase and oxidase-negative. [3]

The different types of infections caused by GAS are produced in varying manners. For instance, GAS pharyngitis is caused by the transmission of bacteria from an infected individual through contact with oral secretions. Conversely, cellulitis secondary to GAS is caused by the direct invasion of bacteria through breakdown/wounds in the skin, which can subsequently progress to necrotizing fasciitis. Similarly, impetigo and erysipelas are caused by direct invasion through breaks in the skin’s protective barrier.

Epidemiology

GAS exclusively infects human beings. [3] The epidemiology of infections secondary to GAS varies depending on the type of infection. Pharyngitis secondary to GAS occurs primarily in children from 5 to 15 years of age. It can also be seen in adults but less frequently. Typically, pharyngitis secondary to GAS occurs most often in the winter and early spring. Overall, among patients with pharyngitis, about 15 to 30 percent of cases in children and 5 to 10 percent of cases in adults are caused by acute GAS infection.[4] Cellulitis and erysipelas are two other syndromes caused by various invasive bacteria, with approximately 10% of cases caused by GAS alone and a large number caused by mixed bacteria, including GAS.[5] Similar to cellulitis, impetigo is caused by several different bacteria; however, just under half of the cases are caused by infection with GAS.[6]

Less commonly found are the more invasive infections of toxic shock syndrome and necrotizing fasciitis. Toxic shock syndrome has been found in population-based European surveillance data to have an incidence of about 3 cases per 100,000 individuals per year with no specific peak age or demographic for infection.[7] With regard to necrotizing fasciitis, population-based data from the United States has an estimated rate of 2.5 cases per 1,000,000 person-years.[8]

Pathophysiology

Recent advances in genetic techniques have allowed a more detailed analysis of the virulence of group A streptococci and how these factors function to promote infection with GAS. On the surface of GAS cells are found molecules of lipoteichoic acid and protein F, which help with adherence to host cells and successful colonization. GAS also produces chemicals called streptolysins and hyaluronidase, which function to destroy host tissues, thereby allowing GAS to spread through the host. Additionally, GAS has several factors, including its capsule, protein G, C5a peptidase as well as protein M, which function to protect GAS from host immune defenses. M protein, in particular, is thought to cause much of the virulence of GAS as it inhibits phagocytosis by host immune cells.[9]

History and Physical

Given that group A streptococci have multiple typical associated infections, each infection type is typified by its own unique characteristics found during the initial history and physical (see Image. Comparisons of Hemolytic Activity for Groups A, B, G, and F Streptococci). 

For those experiencing pharyngitis secondary to GAS, the most common presenting features in the history are fever and sore throat, typically sudden in onset. Additionally, many patients complain of some combination of headache, nausea/vomiting, and abdominal pain. Also frequently found in history is close contact with an individual known to have a case of GAS. This is because frequently, there is a high prevalence in the community when new cases of GAS are detected. Associated physical exam findings of GAS pharyngitis include generalized inflammation of the tonsils and pharynx with variable exudate. Also frequently found on the exam are tender cervical lymph nodes (lymphadenitis), red and swollen uvula, palatal petechiae, and sometimes a scarlatiniform rash. Conjunctivitis, cough, coryza, or diarrhea are very infrequently found, and the presence of these points much more toward a viral cause of symptoms.[4]

Impetigo is a clinical diagnosis typically found in school-aged children. These children typically appear well on their initial presentation without acute signs of distress. They will present with cutaneous lesions that appear as discrete to confluent ‘honey-crusted’ lesions that typically appear on the face and/or extremities. Typically, no vital sign abnormalities are associated with the clinical presentation, and the patient will have no associated physical exam findings apart from the characteristic lesions.[6]

The more invasive GAS infection resulting in necrotizing fasciitis produces more severe symptoms found on the history and physical. Typically, these infections initially appear somewhat benign with an area of slightly reddened/inflamed soft tissue, which can mimic simple cellulitis. However, one key finding early on is a disproportionately high amount of pain with the observed lesion. Following this, there is usually a rapid migration/spread of the erythema, often greater than 1cm/hour, despite treatment with IV antibiotics. Subsequently, blisters and bullae can form, which typically drain either serosanguineous or hemorrhagic fluid. The skin, at this point, will often turn necrotic and begin sloughing. Many times, crepitus will be found as subcutaneous gas is produced. Once further along in the clinical course, the pain will lessen significantly as the infection destroys the cutaneous nerves. Throughout the course of necrotizing fasciitis, patients will experience fever and chills and, in more severe cases, will demonstrate hypotension and tachycardia typical of sepsis.[10]

Another serious and life-threatening condition caused by GAS is toxic shock syndrome. Toxic shock syndrome is caused by invasive infection by GAS, resulting in bacterial enterotoxins being released and systemic symptoms. These invasive infections can result from primary infection by GAS in many sites, especially deep wound infections. These patients clinically present with symptoms of severe sepsis with tachycardia, hypotension, poor tissue profusion, and signs of end-organ dysfunction.[7]

Evaluation

As discussed previously, several infections secondary to GAS are diagnosed based on history and physical alone, especially in the case of infections such as cellulitis, impetigo, and necrotizing fasciitis. Other infections, such as those causing toxic shock syndrome, can be suspected clinically; however, they are most effectively evaluated with blood cultures to identify the causative organism to tailor appropriate antibiotic therapy. 

Pharyngitis secondary to GAS is one area where there have been significant recommendations regarding appropriate testing. The primary reason is that the testing currently employed demonstrates a small amount of false-negative and false-positive rates, which may result in inappropriate treatment or lack thereof if the testing is not used appropriately. Throat swab cultures are the gold standard for identifying cases of GAS pharyngitis. However, these results are not available for 24 hours or longer. Rapid swabs for GAS have a specificity of greater than 90 percent, but the sensitivity is still only between 80 to 90 percent. In children, the rate of infection is high enough (high pretest probability) that a positive rapid swab results in a high enough post-test probability that there is no need for a confirmatory throat culture to confirm the diagnosis of GAS pharyngitis. Conversely, in adults, given the low general rate of pharyngitis due to GAS (and therefore low pretest probability), it is actually a negative rapid swab that does not need to be confirmed by culture as a negative rapid swab confers an extremely low post-test probability of infection with GAS.[4][11]

GAS grows easily on sheep blood agar, is a Gram-positive coccus, and is arranged in chains. GAS is both catalase and oxidase-negative. COnfirmatory identification is done using Lancefield grouping and, more recently, using techniques such as the MALDI-TOF. [3][12]

Treatment / Management

Given that all infections due to GAS are bacterial in nature, the mainstay in treatment is targeted antibiotic therapy. In most cases of infection due to GAS, antibiotic treatment can actually be started before confirmatory laboratory results are available. However, it logically follows that if testing is ultimately negative for GAS, antibiotics specifically targeted against GAS should be discontinued.

When considering antibiotics for treating GAS, several options are available. Penicillin-based antibiotics, including ampicillin and amoxicillin, are very effective in treating GAS infections. Given their similar mechanism of action, cephalosporins, in addition to macrolides and clindamycin, have shown appropriate activity against GAS.

Specifically, when treating GAS pharyngitis and simple cellulitis, an oral regimen of the above antibiotics is typically recommended for about ten days in pharyngitis and 5 to 7 days in cellulitis. A typical regimen can be IV benzylpenicillin for ten days or Penicillin V as an oral alternative for ten days in pharyngitis. An alternate treatment specifically for pharyngitis due to GAS is a single dose of intramuscular penicillin G benzathine, especially in those patients who are unlikely to complete the full course of oral antibiotics. [4]

For more severe infections secondary to GAS, including necrotizing fasciitis and toxic shock syndrome, the causative bacteria is typically not known at the time of the patient’s presentation. Given the life-threatening nature of these infections, it is recommended that more broad-spectrum antibiotics be given in IV form. This ensures that both GAS, as well as other possible causative organisms are treated while awaiting final speciation results.[7] In addition to antibiotics for these severe/systemic infections, supportive measures should also be taken, including fluid resuscitation, blood pressure management with vasopressors, etc.[13][14]

Differential Diagnosis

As mentioned earlier, many bacterial and viral pathogens can cause identical presentations to those infections caused by GAS. Each infection must be evaluated with the previously mentioned bacterial cultures and/or swabs to evaluate for GAS versus other bacterial or viral infections. Additionally, several non-infectious conditions can closely resemble GAS infections. Cellulitis, in particular, has a very similar presentation to both venous stasis changes and the same findings noted with an acute DVT, especially when symptoms are present in the lower extremities. Therefore, when evaluating a patient with lower extremity pain, redness, and/or swelling, it is essential to keep these conditions in mind. In many cases, venous stasis changes are found bilaterally, which is much less commonly found in cellulitis, which could point toward the appropriate diagnosis. Conversely, unilateral redness, swelling, and/or pain could represent either an acute deep vein thrombosis or cellulitis; therefore, ultrasonography is often needed to make the correct diagnosis.[10]

Prognosis

Generally, the prognosis for the less severe infections secondary to GAS is good, with very low morbidity and mortality rates. This is true of pharyngitis, cellulitis, and impetigo, which are effectively treated with standard oral antibiotic therapy and, in the vast majority of cases, even resolve spontaneously without medical intervention. Given the exceedingly low mortality rate from these types of infections, there is very little data to accurately quantify annual mortality rates.

On the other hand, the more invasive and severe infections caused by GAS do carry with them a significant mortality and morbidity rate. Based on most recent studies, toxic shock syndrome carries approximately a 5 to 10% mortality rate with a worse prognosis for those at the extremes of age and those with preexisting conditions. Even worse, mortality rates are present in those diagnosed with necrotizing fasciitis. Recent data have demonstrated mortality rates between 25% and 35% and a nearly ubiquitous need for surgical intervention, which adds to morbidity for those who survive their infection. An even worse prognosis exists for those concurrently diagnosed with toxic shock syndrome and necrotizing fasciitis, as these individuals have mortality rates up to 60%.[7][11]

Complications

Apart from the morbidity and mortality associated with severe infections caused by GAS, the one major complication that can result from even minor infections is acute rheumatic fever. This is an autoimmune response typically to GAS pharyngitis. This leads to illness typified by joint pain and/or swelling, fever, chorea, skin and subcutaneous changes, and cardiac valvular regurgitation. The symptoms of acute rheumatic fever can be severe, with significant edema due to heart failure, severe joint pain, high fevers, and choreiform movements that prevent the normal performance of activities of daily living.

This diagnosis typically requires management in the hospital for evaluation of the extent of symptoms with an echocardiogram, etc. First, the mainstay of treatment is the eradication of GAS from the body with antibiotics. Subsequently, in severe disease, corticosteroids or non-steroidal anti-inflammatory medications may be employed. In cases of chorea, antiepileptics may be needed, and aggressive management of heart failure symptoms may be necessary for those experiencing fluid overload due to valvular regurgitation. The valvular regurgitation associated with acute rheumatic fever may be permanent and, in some cases, is severe enough to require definitive surgical management with valve repair/replacement.[15] Another possible complication of GAS infection is post-streptococcal glomerular nephritis.

Deterrence and Patient Education

As with any viral or bacterial infection, isolation and avoidance of exposure are essential to avoid contracting the infection. This is especially true in cases of impetigo and strep pharyngitis, as these infections are much more common in children. As such, children have a higher propensity to spread this infection through close contact with other children. Therefore, isolating known infections from close contact with others is important by having them remain home from school, daycare, etc. However, because GAS is ubiquitous in our environment and part of our normal skin flora, very little can be done to avoid infection with GAS altogether.

Enhancing Healthcare Team Outcomes

Diagnosing and managing these infections requires an interprofessional healthcare team that includes clinicians (MDs, DOs, NPs, and PAs), infectious disease specialists, nursing staff, and an infectious disease-specialized pharmacist. The aid of a clinical microbiologist should be sought if a GAS infection is suspected or confirmed. Clinicians, particularly infectious disease specialists, will be the primary drivers of managing the case, but consulting with an infectious disease pharmacist will aid in more targeted antimicrobial therapy.  The pharmacist can also counsel the patient on drug therapy, perform medication reconciliation, and educate the patient and team on potential adverse events. Nurses will administer the medication in many instances (particularly in the inpatient setting), monitor antimicrobial therapy, and report any concerns to the team. This interprofessional approach to patient care requires open communication and coordinated therapeutic activity, resulting in optimal patient outcomes. [Level 5]

One of the most critical ways the interprofessional team can improve outcomes in patients with known or suspected infection with GAS is by recognizing the signs of infection. This is especially important in cases of more invasive/severe GAS infections, such as those found with necrotizing fasciitis and toxic shock syndrome. Healthcare professionals must recognize signs of sepsis and shock and pay particular attention to physical exam findings, indicating deep soft tissue infections or systemic signs of infection. In doing this, the clinical outcomes among patients are greatly improved as appropriate antibiotics can be provided promptly with the hope that the spread of the infection and the sequelae of the infection may be more promptly controlled. This requires appropriate coordination of nursing and clinicians to recognize these signs of infections, consultants to aid in achieving a proper diagnosis, and pharmacists to help treat these infections most effectively, considering the clinical presentation and the local antibiotic resistance patterns. [Level 1]



(Click Image to Enlarge)
<p><em>Streptococcus Pyogenes </em>Bacteria

Streptococcus Pyogenes Bacteria. This illustration depicts a photomicrograph of a specimen revealing numbers of chain-linked S pyogenes bacteria.


Public Health Image Library, Public Domain, via Centers for Disease Control and Prevention 


(Click Image to Enlarge)
<p>Comparisons of Hemolytic Activity for Groups A, B, G, and F <em>Streptococci

Comparisons of Hemolytic Activity for Groups A, B, G, and F Streptococci. Group B streptococcus appears as small colorless colonies that cause beta hemolysis.


Centers for Disease Control and Prevention

Details

Editor:

Vikas Gupta

Updated:

2/6/2023 10:19:57 AM

References


[1]

O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, Albanese BA, Farley MM, Barrett NL, Spina NL, Beall B, Harrison LH, Reingold A, Van Beneden C, Active Bacterial Core Surveillance Team. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Oct 1:45(7):853-62     [PubMed PMID: 17806049]


[2]

Martin JM, Green M. Group A streptococcus. Seminars in pediatric infectious diseases. 2006 Jul:17(3):140-8     [PubMed PMID: 16934708]


[3]

Gera K, McIver KS. Laboratory growth and maintenance of Streptococcus pyogenes (the Group A Streptococcus, GAS). Current protocols in microbiology. 2013 Oct 2:30():9D.2.1-9D.2.13. doi: 10.1002/9780471729259.mc09d02s30. Epub 2013 Oct 2     [PubMed PMID: 24510893]


[4]

Schroeder BM, Diagnosis and management of group A streptococcal pharyngitis. American family physician. 2003 Feb 15;     [PubMed PMID: 12613739]


[5]

Bruun T, Oppegaard O, Kittang BR, Mylvaganam H, Langeland N, Skrede S. Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study. Open forum infectious diseases. 2016 Jan:3(1):ofv181. doi: 10.1093/ofid/ofv181. Epub 2015 Nov 25     [PubMed PMID: 26734653]


[6]

Pereira LB. Impetigo - review. Anais brasileiros de dermatologia. 2014 Mar-Apr:89(2):293-9     [PubMed PMID: 24770507]


[7]

Schmitz M, Roux X, Huttner B, Pugin J. Streptococcal toxic shock syndrome in the intensive care unit. Annals of intensive care. 2018 Sep 17:8(1):88. doi: 10.1186/s13613-018-0438-y. Epub 2018 Sep 17     [PubMed PMID: 30225523]


[8]

Arif N,Yousfi S,Vinnard C, Deaths from necrotizing fasciitis in the United States, 2003-2013. Epidemiology and infection. 2016 Apr;     [PubMed PMID: 26548496]


[9]

Heath A, DiRita VJ, Barg NL, Engleberg NC. A two-component regulatory system, CsrR-CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B. Infection and immunity. 1999 Oct:67(10):5298-305     [PubMed PMID: 10496909]


[10]

Bellapianta JM, Ljungquist K, Tobin E, Uhl R. Necrotizing fasciitis. The Journal of the American Academy of Orthopaedic Surgeons. 2009 Mar:17(3):174-82     [PubMed PMID: 19264710]


[11]

Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerging infectious diseases. 1995 Jul-Sep:1(3):69-78     [PubMed PMID: 8903167]


[12]

Wang J,Zhou N,Xu B,Hao H,Kang L,Zheng Y,Jiang Y,Jiang H, Identification and cluster analysis of Streptococcus pyogenes by MALDI-TOF mass spectrometry. PloS one. 2012     [PubMed PMID: 23144803]


[13]

Stevens DL. Invasive group A streptococcal disease. Infectious agents and disease. 1996 Jun:5(3):157-66     [PubMed PMID: 8805078]


[14]

Stevens DL. Invasive group A streptococcus infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1992 Jan:14(1):2-11     [PubMed PMID: 1571429]


[15]

Carapetis JR, Beaton A, Cunningham MW, Guilherme L, Karthikeyan G, Mayosi BM, Sable C, Steer A, Wilson N, Wyber R, Zühlke L. Acute rheumatic fever and rheumatic heart disease. Nature reviews. Disease primers. 2016 Jan 14:2():15084. doi: 10.1038/nrdp.2015.84. Epub 2016 Jan 14     [PubMed PMID: 27188830]